###begin article-title 0
Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupuslike autoimmune disease
###end article-title 0
###begin p 1
###xml 26 43 26 43 <email xmlns:xlink="http://www.w3.org/1999/xlink">p.wang@qmul.ac.uk</email>
CORRESPONDENCE Ping Wang: p.wang@qmul.ac.uk
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 293 297 293 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 384 388 384 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 402 405 402 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 498 499 498 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 503 507 503 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 683 684 679 680 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Maintaining tolerance of T cells to self-antigens is essential to avoid autoimmune disease. How self-reactive T cells are kept functionally inactive is, however, unknown. In this study, we show that early growth response gene 2 (Egr-2), a zinc-finger transcription factor, is expressed in CD44high T cells and controls their proliferation and activation. In the absence of Egr-2, CD44high, but not CD44low T cells, are hyperreactive and hyperproliferative in vivo. The accumulation of activated CD4+CD44high T cells leads to the development of a late onset lupuslike autoimmune disease characterized by the accumulation of interferon (IFN)-gamma and interleukin (IL)-17-producing CD4+ T cells, loss of tolerance to nuclear antigens, massive infiltration of T cells into multiple organs and glomerulonephritis. We found that the expression of cyclin-dependent kinase inhibitor p21cip1 was impaired in Egr-2-deficient T cells, whereas the expression of IFN-gamma and IL-17 in response to T cell receptor ligation was significantly increased, suggesting that Egr-2 activates the expression of genes involved in the negative regulation of T cell proliferation and inflammation. These results demonstrate that Egr-2 is an intrinsic regulator of effector T cells and controls the expansion of self-reactive T cells and development of autoimmune disease.
###end p 3
###begin p 4
Abbreviations used: APC, allophycocyanin; ChIP, chromatin immunoprecipitation; cKO, conditional KO; ds, double stranded; Egr-2, early growth response gene 2.
###end p 4
###begin p 5
B. Zhu and A.L.J. Symonds contributed equally to this paper.
###end p 5
###begin p 6
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 798 799 798 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 801 802 801 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 804 805 804 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 807 808 807 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 810 811 810 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
The engagement of the T cell receptor with antigen can lead to an immune response, tolerance, or homeostatic proliferation, depending on the properties of the antigen and the context in which it is encountered (1). The outcome of a T cell response to antigen stimulation is regulated by the interplay and complex interaction of positive (stimulatory) and negative (inhibitory) pathways. In optimal immune responses, antigen and costimulatory molecules from activated antigen-presenting cells induce strong mitogenic signals in naive T cells, leading to proliferation and differentiation of effector T cells. However, under tolerant or homeostatic conditions, such as the lack of costimulatory signals or self-antigen stimulation, T cells either do not respond or undergo homeostatic proliferation (2, 3, 4, 5, 6). The molecular pathways controlling the different responses after TCR engagement are largely unknown.
###end p 6
###begin p 7
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 503 504 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 509 510 509 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 652 653 652 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 724 725 724 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 727 728 727 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 968 970 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 902 906 <span type="species:ncbi:10090">mice</span>
Recently, we and others have found that Egr-2 is induced in tolerant T cells in response to antigen stimulation in vivo or TCR ligation in vitro (7, 8, 9). Egr-2 is a member of a family of zinc finger proteins, which consists of four members, Egr-1, -2, -3, and -4, and has been found to play a critical role in hindbrain development and myelination of the peripheral nervous system (10, 11). Together with Egr-1 and -3, Egr-2 is expressed in thymocytes (12) and in mature T cells upon TCR stimulation (7, 8, 9). RNA interference (RNAi)-mediated knockdown of Egr-2 in an established T cell line rendered the cells less susceptible to anergy induction (7), whereas overexpression of Egr-2 reduced T cell activation in vitro (7, 8) indicating that Egr-2 regulates genes involved in the suppression of T cell activation. However, the function of Egr-2 in T cells in vivo has not been studied, as Egr-2 KO mice die perinatally because of defects in hindbrain development (11).
###end p 7
###begin p 8
###xml 296 297 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 597 601 597 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
###xml 625 629 <span type="species:ncbi:10090">mice</span>
In this study, we demonstrate that Egr-2 is expressed in effector phenotype T cells in the absence of obvious antigen stimulation in vivo. To assess the function of Egr-2 in T cells in vivo, we established Egr-2 conditional KOs (Egr-2 cKO), in which the Egr-2 gene was deleted specifically in CD2+ lymphocytes. The Egr-2-deficient T cells did not show altered primary activation, but were hyperproliferative in response to prolonged stimulation and exhibited a Th1 and Th17 bias leading to the development of a lupuslike syndrome in older mice. Defective expression of p21cip1 was detected in CD44high T cells from Egr-2 cKO mice, and Egr-2 was found to interact directly with the promoter of p21cip1 in vivo. In addition, IFN-gamma and IL-17 were highly induced in Egr-2-deficient T cells, and accumulation of IFN-gamma- and IL-17-producing cells was associated with massive infiltration of T cells in multiple organs. Our results demonstrate that Egr-2 is important for controlling the self-tolerance of T cells and preventing autoimmunity through activation of negative regulators of cell proliferation and by controlling proinflammatory cytokine expression.
###end p 8
###begin title 9
RESULTS
###end title 9
###begin title 10
Egr-2 negatively regulates the proliferation of activated T cells, but not naive T cells
###end title 10
###begin p 11
###xml 88 89 88 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 444 452 444 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 204 219 <span type="species:ncbi:10090">transgenic mice</span>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 438 442 <span type="species:ncbi:10090">mice</span>
###xml 529 533 <span type="species:ncbi:10090">mice</span>
In previous studies, we and others found that Egr-2 can be induced in tolerant T cells (7, 8, 9). To study the function of Egr-2 in T cells in vivo, we established Egr-2 cKO by crossing hCD2 promoter-cre transgenic mice (13) with Egr-2-flox/flox mice (14). Egr-2 WT alleles, floxed alleles, and the presence of the hCD2-cre transgene were determined by PCR (Fig. S1, available at ). Egr-2 was completely deleted from T cells in Egr-2 cKO mice (Fig. 1 A). However, expression of Egr-2 was still detected in B cells from Egr-2 cKO mice (Fig. S1), which is consistent with the weak activity of the CD2 promoter in B cells (13).
###end p 11
###begin p 12
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Enhanced proliferative responses of Egr-2&#8211;deficient T cells to sustained IL-2 stimulation.</bold>
###xml 498 499 495 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 640 641 637 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
###xml 541 545 <span type="species:ncbi:10090">mice</span>
Enhanced proliferative responses of Egr-2-deficient T cells to sustained IL-2 stimulation. hCD2-Cre/Egr-2 floxed mice were identified by PCR with primer pairs specific for iCre, WT Egr-2, and floxed Egr-2 (Fig. S1). (A) The expression of Egr-2 in T cells from spleens of Egr-2 cKO and WT mice before and after TCR ligation in vitro was examined by real-time RT-PCR and immunoblotting. The relative expression of Egr-2 mRNA was measured after normalizing against beta-actin. (B) Proliferation of CD4+ T cells from spleens of Egr-2 cKO and WT mice was analyzed in response to anti-CD3/CD28-coated beads or uncoated beads as a control. (C) CD4+ T cells were first stimulated for 48 h with anti-CD3 (1degrees), and then expanded in 100 U/ml IL-2 for 3 d. The cells were then recounted and restimulated with IL-2 (2degrees) at different concentrations as indicated. The data are representative of three to five experiments.
###end p 12
###begin p 13
The deletion of Egr-2 did not alter the development of the major thymocyte subsets, regulatory T cells, and major subgroups of peripheral T and B cells (Figs. S2 and S3, available at ).
###end p 13
###begin p 14
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 255 263 255 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 476 484 476 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 766 768 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 470 474 <span type="species:ncbi:10090">mice</span>
###xml 589 604 <span type="species:ncbi:10090">transgenic mice</span>
###xml 698 702 <span type="species:ncbi:10090">mice</span>
###xml 793 797 <span type="species:ncbi:10090">mice</span>
In contrast to the suppressive role of Egr-2 discovered by Egr-2 knockdown in a T cell line (7), the activation of Egr-2 cKO T cells in response to primary TCR stimulation was not altered as indicated by normal levels of ERK activation and proliferation (Fig. 1 B and Fig. S4, available at ). However, after primary stimulation, under the condition of sustained IL-2 exposure, Egr-2-deficient T cells started to proliferate much faster than T cells from Egr-2-flox/flox mice (Fig. 1 C). To exclude possible effects of the Cre transgene on T cell activation, T cells from hCD2 promoter-cre transgenic mice were also used for stimulation and showed the same responses as T cells from Egr-2-flox/flox mice (unpublished data), which is consistent with previous reports (13). Thus, Egr-2-flox/flox mice were used as a WT control.
###end p 14
###begin p 15
###xml 53 57 <span type="species:ncbi:10090">mice</span>
The enhanced proliferation of T cells from Egr-2 cKO mice did not result from alteration of IL-2 signaling, as indicated by a normal level of STAT5 activation in Egr-2-deficient T cells in response to TCR ligation (Fig. S4). These results suggest that Egr-2 controls the turnover of effector T cells, rather than primary T cell activation.
###end p 15
###begin p 16
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
Egr-2 has been found to induce expression of FasL in activated T cells (15, 16). However, we could not detect alterations in FasL expression and apoptosis in Egr-2-deficient T cells before or after TCR ligation (Fig. S5, available at ). Collectively, these data suggest that Egr-2 does not affect TCR signaling or apoptosis induction, but instead controls the subsequent expansion of activated T cells.
###end p 16
###begin title 17
###xml 26 30 26 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
Egr-2 is expressed in CD44high T cells and is required for controlling the proliferation and activation of T cells in vivo
###end title 17
###begin p 18
###xml 308 312 308 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 455 456 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 491 495 491 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 598 599 598 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 605 606 605 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 648 652 648 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 661 664 661 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 677 678 677 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 682 683 682 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 687 691 687 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 699 700 699 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 704 705 704 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 709 712 709 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 814 815 814 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 819 823 819 823 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 880 881 880 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 885 888 885 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 901 909 901 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 963 964 963 964 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 968 972 968 972 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 982 990 982 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 1135 1139 1135 1139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 1286 1290 1286 1290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 1296 1299 1296 1299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 1457 1465 1457 1465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1499 1500 1499 1500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1549 1553 1549 1553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 1563 1566 1563 1566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 1592 1593 1592 1593 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1614 1622 1614 1622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1673 1677 1673 1677 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 2017 2018 2017 2018 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2022 2026 2022 2026 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 2043 2044 2043 2044 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2048 2052 2048 2052 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 2104 2112 2104 2112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 2149 2150 2149 2150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2154 2158 2154 2158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 2166 2167 2166 2167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2171 2175 2171 2175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 2256 2264 2256 2264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 2287 2290 2287 2290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 2344 2345 2344 2345 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2349 2352 2349 2352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 2399 2407 2399 2407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 2469 2473 2469 2473 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 2498 2501 2498 2501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 2627 2631 2627 2631 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 2673 2674 2673 2674 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2681 2682 2681 2682 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2810 2814 2810 2814 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 2836 2840 2836 2840 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 2896 2900 2896 2900 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 2921 2929 2921 2929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 2974 2978 2974 2978 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 754 758 <span type="species:ncbi:10090">mice</span>
###xml 1258 1262 <span type="species:ncbi:10090">mice</span>
###xml 1417 1421 <span type="species:ncbi:10090">mice</span>
###xml 1451 1455 <span type="species:ncbi:10090">mice</span>
###xml 1535 1539 <span type="species:ncbi:10090">mice</span>
###xml 1608 1612 <span type="species:ncbi:10090">mice</span>
###xml 1699 1703 <span type="species:ncbi:10090">mice</span>
###xml 1761 1766 <span type="species:ncbi:10090">mouse</span>
###xml 1914 1918 <span type="species:ncbi:10090">mice</span>
###xml 2076 2080 <span type="species:ncbi:10090">mice</span>
###xml 2217 2221 <span type="species:ncbi:10090">mice</span>
###xml 2393 2397 <span type="species:ncbi:10090">mice</span>
###xml 2705 2709 <span type="species:ncbi:10090">mice</span>
###xml 2768 2772 <span type="species:ncbi:10090">mice</span>
###xml 2864 2868 <span type="species:ncbi:10090">mice</span>
###xml 2915 2919 <span type="species:ncbi:10090">mice</span>
###xml 3002 3006 <span type="species:ncbi:10090">mice</span>
The hyperproliferation of Egr-2-deficient T cells in response to sustained, but not primary, stimulation suggests that Egr-2 deficiency may have more profound effects on T cells that have differentiated to an effector phenotype, rather than naive T cells in vivo. In the absence of antigen immunization, CD44high effector phenotype T cells are predominantly the result of exposure to environmental antigen, such as gut flora, or to certain self-antigens (2). Therefore, the responses of CD44high T cells have to be controlled to prevent the development of autoimmune or hypersensitivity reactions (1, 3 - 6). To investigate Egr-2 expression in CD44high and CD44low T cells, CD4+CD25-CD44high and CD4+CD25-CD44low T cells were isolated from spleens of WT mice by FACS. Egr-2 transcripts were highly expressed in CD4+CD44high T cells in contrast to the minimal expression in the CD4+CD44low population (Fig. 2 A). Furthermore, Egr-2 protein was only detected in CD4+CD44high T cells (Fig. 2 A). These results demonstrate that Egr-2 is expressed in effector phenotype T cells in vivo. To investigate the effect of Egr-2 deficiency on CD44high T cells, we examined their population at 3, 8, and 15 mo of age and their proliferative potential in WT and Egr-2 cKO mice. The percentage of CD44high CD62Llow cells, which is characteristic of effector phenotype T cells, was normal at 3 mo, but increased at 8 mo in Egr-2 cKO mice compared with age-matched WT mice (Fig. 2 B). At 15 mo of age, all of the CD4+ T cells from spleens of Egr-2 cKO mice were CD44high and CD62Llow in contrast to 21% of CD4+ T cells in WT mice (Fig. 2 B). In contrast to the dramatic accumulation of CD44high T cells in Egr-2 cKO mice, B cells, NK cells, and macrophages were similar in both mouse types (Fig. S6, available at ). To assess the proliferative potential of these cells in vivo in the absence of experimental immunization, 8-mo-old mice were fed BrdU for 9 d, and then splenic T cells were analyzed for BrdU incorporation. 29.5% of CD8+CD44high and 21.5% of CD4+CD44high T cells from Egr-2 cKO mice had incorporated BrdU (Fig. 3 A). In contrast, the percentage of CD8+CD44high and CD4+CD44high cells that had incorporated BrdU from WT mice was 14.1 and 12.1%, respectively (Fig. 3 A). Less than 5% of CD44low T cells incorporated BrdU, and the proportion of BrdU+CD44low T cells was similar in Egr-2 cKO and WT mice (Fig. 3 A). One possible explanation for the hyperproliferation of CD44high cells is that naive CD44low T cells have impaired survival in the absence of Egr-2, and that the resulting lymphopenia induces hyperproliferation of CD44high T cells. To exclude this possibility, CD4+ or CD8+ T cells from 7-mo-old mice were labeled with CFSE and adoptively transferred into WT mice. Consistent with the increase of CD44high T cells in vivo, CD44high T cells from Egr-2 cKO mice proliferated more than CD44high cells from WT mice (Fig. 3 B), indicating that hyperproliferation of CD44high T cells from Egr-2 cKO mice is driven by an intrinsic mechanism.
###end p 18
###begin p 19
###xml 25 29 25 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 0 46 0 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Egr-2 expression and CD44<sup>high</sup> T cells in vivo.</bold>
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 64 67 64 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 75 76 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 85 89 85 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 517 518 514 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 428 432 <span type="species:ncbi:10090">mice</span>
Egr-2 expression and CD44high T cells in vivo. (A) CD4+CD25-CD44low and CD4+CD25-CD44high T cells were sorted from splenocytes of WT mice at 8 mo of age by FACS. The expression of Egr-2 in these two populations was examined by real-time RT-PCR and immunoblotting. The relative expression of Egr-2 mRNA was normalized to beta-actin mRNA. The results are representative of three experiments. (B) Splenocytes from Egr-2 cKO and WT mice of different ages were stained for CD4, CD44, and CD62L. Cells were gated on the CD4+ population.
###end p 19
###begin p 20
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Proliferation of T cells in Egr-2 cKO mice.</bold>
###xml 328 329 328 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 333 337 333 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 346 349 346 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 354 355 354 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 359 363 359 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 371 372 371 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 376 379 376 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 395 396 395 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 403 404 403 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 655 659 655 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 667 670 667 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 48 52 <span type="species:ncbi:10090">Mice</span>
###xml 448 452 <span type="species:ncbi:10090">mice</span>
###xml 559 563 <span type="species:ncbi:10090">mice</span>
Proliferation of T cells in Egr-2 cKO mice. (A) Mice at 8 mo of age were fed BrdU in drinking water for 9 d. At the end of BrdU treatment, splenocytes were stained with cocktails of anti-CD8, anti-CD44, and anti-BrdU (bottom) or anti-CD4, anti-CD44, and anti-BrdU (top). BrdU-positive T cells were quantified after gating on CD4+CD44high, CD4CD44low, CD8+CD44high, or CD8+CD44low cells. (B). CD4+ or CD8+ T cells were purified from Egr-2 cKO or WT mice at 7 mo of age and labeled with CFSE. The labeled cells were adoptively transferred into syngenic C57BL/6 mice. 3 wk after transfer, splenocytes were stained with anti-CD44. Cells were gated on the CD44high or CD44low population, CFSE dilution was analyzed, and the percentage of cells that had divided was quantified. Data are representative of three experiments.
###end p 20
###begin p 21
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 50 54 50 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 256 264 256 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 390 398 390 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
###xml 250 254 <span type="species:ncbi:10090">mice</span>
###xml 322 326 <span type="species:ncbi:10090">mice</span>
###xml 384 388 <span type="species:ncbi:10090">mice</span>
Consistent with the hyperproliferation of CD4+CD44high T cells, by 15 mo of age, most of the Egr-2 cKO mice developed a spontaneous lymphoproliferative disorder manifesting as splenomegaly, with a spleen size two to five times larger than that of WT mice (Fig. 4 A). The T cell population in the spleens of aged Egr-2 cKO mice was significantly increased compared with age-matched WT mice (Fig. 4 A).
###end p 21
###begin p 22
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Proliferation and activation of T cells in Egr-2 cKO mice.</bold>
###xml 134 135 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 143 144 143 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 223 224 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 231 232 229 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
Proliferation and activation of T cells in Egr-2 cKO mice. (A) Spleen size in 15-mo-old Egr-2 cKO and WT mice, and total number of CD4+ and CD8+ T cells in spleens from these mice; presented as mean +/- SD. (B) Isolated CD4+ or CD8+ T cells from spleens of Egr-2 cKO and WT mice were stained for surface markers, as indicated. Bar, 5 mm.
###end p 22
###begin p 23
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 158 159 158 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 166 167 166 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 192 200 192 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 409 413 409 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
In addition to the increase in T cell numbers, most CD4+ and nearly half of CD8+ cells from Egr-2 cKO mice expressed CD25, CD44, and CD69, whereas <20% of CD4+ or CD8+ cells from WT mice did (Fig. 4 B), suggesting that the T cells in aged Egr-2 cKO mice are predominately effector phenotype cells. These results demonstrate that loss of Egr-2 leads to the hyperproliferation and accumulation of activated CD44high T cells in vivo, indicating an intrinsic proliferative disorder of effector T cells.
###end p 23
###begin title 24
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Development of lupuslike autoimmune disease in Egr-2 cKO mice
###end title 24
###begin p 25
###xml 220 224 220 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 947 962 947 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, A and B</xref>
###xml 1079 1087 1079 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 1193 1201 1193 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 D</xref>
###xml 1228 1236 1228 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 E</xref>
###xml 1291 1299 1291 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 1412 1420 1412 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 F</xref>
###xml 1594 1602 1594 1602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 D</xref>
###xml 1971 1979 1971 1979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 2090 2098 2090 2098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 2245 2253 2245 2253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 2384 2385 2384 2385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2389 2393 2389 2393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 2403 2411 2403 2411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 2472 2476 2472 2476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 2698 2706 2698 2706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 2779 2787 2779 2787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 260 264 <span type="species:ncbi:10090">mice</span>
###xml 429 433 <span type="species:ncbi:10090">mice</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 596 600 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
###xml 679 683 <span type="species:ncbi:10090">mice</span>
###xml 715 719 <span type="species:ncbi:10090">mice</span>
###xml 761 765 <span type="species:ncbi:10090">mice</span>
###xml 831 835 <span type="species:ncbi:10090">mice</span>
###xml 1113 1117 <span type="species:ncbi:10090">mice</span>
###xml 1389 1393 <span type="species:ncbi:10090">mice</span>
###xml 1406 1410 <span type="species:ncbi:10090">mice</span>
###xml 1497 1501 <span type="species:ncbi:10090">mice</span>
###xml 1775 1779 <span type="species:ncbi:10090">mice</span>
###xml 1858 1862 <span type="species:ncbi:10090">mice</span>
###xml 1917 1921 <span type="species:ncbi:10090">mice</span>
###xml 1965 1969 <span type="species:ncbi:10090">mice</span>
###xml 2084 2088 <span type="species:ncbi:10090">mice</span>
###xml 2239 2243 <span type="species:ncbi:10090">mice</span>
###xml 2427 2431 <span type="species:ncbi:10090">mice</span>
###xml 2692 2696 <span type="species:ncbi:10090">mice</span>
###xml 2932 2947 <span type="species:ncbi:10090">transgenic mice</span>
###xml 2962 2977 <span type="species:ncbi:10090">transgenic mice</span>
###xml 3080 3084 <span type="species:ncbi:10090">mice</span>
###xml 3232 3237 <span type="species:ncbi:9606">human</span>
We have now provided evidence that Egr-2 plays a central role in the control of effector T cell proliferation and activation in vivo. The absence of Egr-2 resulted in hyperproliferation and accumulation of activated CD44high T cells, suggesting that Egr-2 cKO mice may be more susceptible to autoimmune disease. However, we did not observe any early onset autoimmunity such as diabetes or inflammatory bowel disease in Egr-2 cKO mice younger than 10 mo of age. However, after 1 yr, Egr-2 cKO mice started to show hair loss and became less active. By 15 mo of age, more than half of the Egr-2 cKO mice had died (12 out of 20 mice), whereas no death was observed in age-matched WT mice. In contrast to age-matched WT mice, the majority of the surviving Egr-2 cKO mice exhibited features of systemic lupuslike autoimmune disease. The mice displayed hair loss and skin lesions and an accumulation of inflammatory mononuclear cells in various tissues (Fig. 5, A and B). Importantly, the majority of the infiltrated mononuclear cells were T cells with a smaller proportion of B cells (Fig. 5 C). After 12 mo, Egr-2 cKO mice showed signs of severe glomerulonephritis with high levels of proteinuria (Fig. 5 D), glomerular alterations (Fig. 5 E), and inflammatory cell infiltrates into the kidneys (Fig. 5 B). Kidney histology revealed deposition of immune complexes in the glomeruli of Egr-2 cKO mice, but not WT mice (Fig. 5 F). Although the clinical symptoms of lupuslike disease were only observed in mice older than 12 mo, the glomerular IgG deposits and proteinuria could be detected after 8 mo (Fig. 5 D). We did not observe a difference between the two genders in susceptibility to disease development. To further investigate the lupuslike autoimmunity observed in Egr-2 cKO mice, total serum Ig and Ig subclass distribution was measured in WT and Egr-2 cKO mice aged between 6 and 12 mo. Total serum Ig in Egr-2 cKO mice was increased compared with age matched WT mice (Fig. 6 A). Importantly, among the Ig subclasses, only IgG2a was significantly increased in the sera of Egr-2 cKO mice (Fig. 6 A), indicating a Th1-driven response. Crucially, both anti-double-stranded DNA (dsDNA) and -histone autoantibodies were detected in Egr-2 cKO mice (Fig. 2 B). The titer of autoantibodies against dsDNA and histone increased with age and was closely associated with the accumulation of CD4+CD44high T cells (Fig. 3 B). In Egr-2 cKO mice aged 2-3 mo, both the percentage of CD44high T cells in the spleen and the level of anti-dsDNA and -histone autoantibodies were normal. A low level of autoantibodies was detected after 6 mo, and this increased with age, reaching a very high level in 12-mo-old mice (Fig. 6 B), mirroring the progressive accumulation of activated effector T cells (Fig. 2 B). Disease development was not influenced by the Cre-transgene because anti-dsDNA and -histone autoantibodies were not detected in aged hCD2-Cre transgenic mice, and hCD2-Cre transgenic mice as old as 20 mo displayed a normal phenotype (unpublished data). Thus, Egr-2 deficiency in T cells in mice of the non-lupus-prone C57BL/6 background leads to the loss of self-tolerance and development of an autoimmune disease similar in many respects to human lupus.
###end p 25
###begin p 26
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Development of lupuslike autoimmunity in older Egr-2 cKO mice.</bold>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
###xml 449 453 <span type="species:ncbi:10090">mice</span>
###xml 632 636 <span type="species:ncbi:10090">mice</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
###xml 732 737 <span type="species:ncbi:10090">mouse</span>
###xml 767 772 <span type="species:ncbi:10090">mouse</span>
###xml 930 934 <span type="species:ncbi:10090">mice</span>
###xml 985 990 <span type="species:ncbi:10090">mouse</span>
Development of lupuslike autoimmunity in older Egr-2 cKO mice. (A) Skin lesions in 15-mo-old Egr-2 cKO mice compared with age-matched WT mice. (B) Photomicrographs of spleen, liver, and kidney tissues from these mice (x10) stained with hematoxylin-eosin (H-E). Note the expansion of white pulp in spleens and inflammatory infiltrates around the blood vessels of liver and kidney of Egr-2 cKO but not WT. (C) Tissue sections of kidney from Egr-2 cKO mice were stained with antibodies against CD3 (red) and B220 (green). The sections were counterstained with DAPI for nuclear staining. (D) Proteinuria in age-matched WT and Egr-2 cKO mice. Data are the mean +/- SD of values from 10 mice/group. (E) Glomeruli of a 15-mo old Egr-2 cKO mouse (top) and an aged-matched WT mouse (bottom). The arrows indicate typical nuclear fragments. (F) Immune complex deposition in glomeruli of 15-mo-old Egr-2 cKO (left), but not in age-matched WT mice (right) as detected by fluorescently labeled anti-mouse Ig (red). The glomeruli were visualized by DAPI counterstaining in F. Bars: (A) 1 cm; (B) 100 mum; (C) 50 mum; (E) 25 mum; (F) 20 mum.
###end p 26
###begin p 27
###xml 0 48 0 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Development of autoantibodies in Egr-2 cKO mice.</bold>
###xml 241 242 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 368 369 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 460 463 458 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 628 629 626 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
###xml 464 468 <span type="species:ncbi:10090">mice</span>
###xml 556 560 <span type="species:ncbi:10090">mice</span>
###xml 634 638 <span type="species:ncbi:10090">mice</span>
Development of autoantibodies in Egr-2 cKO mice. All the antibodies were measured by ELISA and presented either as milligram/milliliter or absorbance (OD). (A) Serum concentration of total Ig and Ig isotypes. Data represent the mean +/- SD, n = 24 aged 6-12 mo. (B) Serum concentration of IgG antibodies against dsDNA and histone in age matched Egr-2 cKO and WT mice (n = 6/group). (C) Serum concentration of IgG antibodies against dsDNA and histone from RAG 2-/- mice that were recipients of T cells from Egr-2 cKO and T cell-depleted splenocytes from WT mice or T cells from WT and T cell-depleted splenocytes from Egr-2 cKO (n = 5 mice/group).
###end p 27
###begin title 28
The autoimmunity in Egr-2 cKO is T cell dependent
###end title 28
###begin p 29
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 446 454 446 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
Egr-2 is expressed in activated B cells. We found that the expression of Egr-2 could still be detected in B cells from Egr-2 cKO mice after cross-linking of surface Ig (Fig. S1), suggesting that the weak activity of the CD2 promoter in B cells could not effectively delete Egr-2 (13). The failure to delete Egr-2 in B cells in Egr-2 cKO mice may be the reason for the normal B cell population and minimal B cell infiltration in inflamed tissues (Fig. 5 C, Fig. S1, and Fig. S3), suggesting that T cells are the driving force for the development of autoimmune disease in Egr-2 cKO.
###end p 29
###begin p 30
###xml 28 29 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 116 117 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 203 204 203 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 330 333 330 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 528 529 528 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 558 566 558 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 C</xref>
###xml 613 614 613 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 686 687 686 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
###xml 661 665 <span type="species:ncbi:10090">mice</span>
To determine whether the CD4+ T cells in Egr-2 cKO could drive the production of autoantibodies, Egr-2-deficient CD4+ T cells were mixed with T cell-depleted splenocytes from syngenic WT mice, and WT CD4+ T cells were mixed with T cell-depleted splenocytes from Egr-2 cKO mice, and these were then adoptively transferred into Rag2-/- mice of the non-autoimmune-prone C57BL/6 background. 75 d after transfer, anti-dsDNA and -histone autoantibodies were detected in the serum of recipients given the mixture of Egr-2-deficient CD4+ T cells and WT non-T cells (Fig. 6 C), but not in the serum of recipients of WT CD4+ T cells mixed with non-T cells from Egr-2 cKO mice, indicating that CD4+ T cells deficient in Egr-2 are responsible for initiating the development of autoimmune disease.
###end p 30
###begin p 31
These results demonstrate that Egr-2 intrinsically controls the tolerance of T cells and prevents the onset of autoimmunity.
###end p 31
###begin title 32
###xml 42 46 42 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
Egr-2 activates p21cip1 expression in CD44high T cells
###end title 32
###begin p 33
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 374 378 374 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 482 483 482 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 487 491 487 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 499 500 499 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 504 507 504 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 564 568 564 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 651 654 651 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 678 686 678 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 766 774 766 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 798 802 798 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 914 918 914 918 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 1025 1029 1025 1029 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
###xml 536 540 <span type="species:ncbi:10090">mice</span>
###xml 672 676 <span type="species:ncbi:10090">mice</span>
###xml 760 764 <span type="species:ncbi:10090">mice</span>
###xml 827 831 <span type="species:ncbi:10090">mice</span>
###xml 1063 1067 <span type="species:ncbi:10090">mice</span>
Previously, we found that p21cip1 is induced in the presence of Egr-2 in T cells (9). There is evidence suggesting that p21cip1 is involved in the homeostasis and self-tolerance of T cells (17, 18, 19). Intriguingly, p21cip1 KO mice also develop lupuslike disease (17). In particular, defective p21cip1 expression may be partly responsible for the hyperproliferation of CD44high T cells in Egr-2 cKO mice. To investigate this possibility we examined the expression of p21cip1 in CD4+CD44high and CD4+CD44low T cells of WT and Egr-2 cKO mice. We found that the CD44high population expressed approximately fivefold higher levels of p21cip1 than the CD44low population in WT mice (Fig. 7 A). This pattern of p21cip1 expression correlates with that of Egr-2 in WT mice (Fig. 2 A). In contrast, the CD44high population in Egr-2 cKO mice had more than a threefold reduction in expression of p21cip1 compared with WT CD44high cells. The expression of p27kip1 was also analyzed, and a similar level of expression was detected in CD44high cells from both WT and Egr-2 cKO mice (unpublished data).
###end p 33
###begin p 34
###xml 51 55 51 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Egr-2 directly activates p21cip1 expression in CD44<sup>high</sup> T cells.</bold>
###xml 72 73 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 93 94 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 98 99 98 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 103 107 103 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
Egr-2 directly activates p21cip1 expression in CD44high T cells. (A) CD4+CD25-CD44low and CD4+CD25-CD44high T cells from WT and Egr-2 cKO mice were isolated by FACS sorting. The expression of p21cip1 was quantified by real-time RT-PCR. The relative expression of p21cip1 mRNA was normalized against beta-actin mRNA. The data shown are representative of three experiments. (B) Identification of an Egr-2 binding site in the promoter region of the p21cip1 gene. (C) Electrophoretic mobility-shift assay to evaluate the binding of Egr-2 to oligonucleotides corresponding to this sequence from the p21cip1 promoter. Nuclear extracts from stimulated and unstimulated MF2.2D9 cells were incubated with radiolabeled oligonucleotides, and complexes were resolved by native gel electrophoresis. Supershift was observed with anti-Egr-2 antibody, but not with anti-Egr-3 antibody. (D) Chromatin immunoprecipitation assay. GFP and Egr-2-expressing MF2.2D9 T cells were cross-linked with formaldehyde and chromatin immunoprecipitated with anti-Egr-2 or irrelevant control antibody. The p21 promoter, but not the SOCS3 CDS, was detected in the immunoprecipitates by semiquantitative PCR. Amplification was in the linear range.
###end p 34
###begin p 35
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 301 309 301 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 B</xref>
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1036 1044 1036 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 C</xref>
###xml 1645 1653 1645 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 D</xref>
###xml 1786 1790 1786 1790 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 1902 1906 1902 1906 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 120 125 <span type="species:ncbi:10090">mouse</span>
###xml 264 269 <span type="species:ncbi:10090">mouse</span>
###xml 1234 1239 <span type="species:ncbi:10090">mouse</span>
###xml 1814 1818 <span type="species:ncbi:10090">mice</span>
To investigate whether Egr-2 can directly regulate p21cip1 expression we analyzed the 10-kb immediately upstream of the mouse p21cip1 transcriptional start site, a potential Egr-2 binding site (20) was identified within a highly conserved regulatory region of the mouse p21cip1 (-56 to -48) promoter (Fig. 7 B). The p21cip1 promoter contains a GAGGGGGCG site with G residues at the 1, 3, 6, 7, and 9 positions that were shown to be important contacts in the crystal structure of DNA-bound Egr-1 (10), which is the closest homologue to Egr-2 in terms of primary structure. To determine whether Egr-2 binds to this potential site, nuclear proteins were extracted from unstimulated and anti-CD3-stimulated MF2.2D9 T cells. Egr-2 was detected only after TCR stimulation of MF2.2D9 cells. Nuclear proteins derived from TCR-stimulated, but not unstimulated, MF2.2D9 cells bound to an oligonucleotide corresponding to this site and the specific interaction was confirmed by a supershift induced by anti-Egr-2 antibody, but not Egr-3 antibody (Fig. 7 C). The slow migration of oligonucleotide-Egr-2 complexes suggests that Egr-2 may complex with additional factors. To assess whether Egr-2 protein associates with the proximal regions of the mouse p21cip1 promoter in Egr-2-expressing MF2.2D9 T cells in vivo, a chromatin immunoprecipitation (ChIP) assay was performed using MF2.2D9 T cells transduced with Egr-2 or GFP control retrovirus. The results showed that the p21cip1 promoter was detected in the Egr-2 precipitates by PCR, whereas no signal above background was seen with irrelevant IgG or with primers specific for the SOCS3 gene as controls (Fig. 7 D), indicating that Egr-2 directly binds to the p21cip1 promoter in T cells. Together with the defective expression of p21cip1 in CD44high T cells from Egr-2 cKO mice, these data suggest that Egr-2 directly activates the expression of p21cip1 in CD44high T cells.
###end p 35
###begin title 36
###xml 36 40 <span type="species:ncbi:10090">mice</span>
T cell differentiation in Egr-2 cKO mice
###end title 36
###begin p 37
###xml 477 478 473 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 591 595 587 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 684 692 680 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 746 754 742 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 A</xref>
###xml 866 874 858 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 A</xref>
###xml 1109 1110 1097 1098 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1120 1128 1108 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 A</xref>
###xml 1346 1347 1330 1331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1562 1570 1530 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 B</xref>
###xml 1775 1783 1715 1723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 B</xref>
###xml 2194 2202 2050 2058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 B</xref>
###xml 526 530 <span type="species:ncbi:10090">mice</span>
###xml 623 627 <span type="species:ncbi:10090">mice</span>
###xml 1383 1387 <span type="species:ncbi:10090">mice</span>
###xml 1486 1490 <span type="species:ncbi:10090">mice</span>
###xml 1672 1676 <span type="species:ncbi:10090">mice</span>
###xml 1769 1773 <span type="species:ncbi:10090">mice</span>
###xml 1960 1964 <span type="species:ncbi:10090">mice</span>
###xml 2055 2059 <span type="species:ncbi:10090">mice</span>
Although p21cip1 deficiency could explain the proliferative disorder of effector T cells, there may be other mechanisms involved in systemic inflammation. To examine the role of Egr-2 in regulation of effector T cell function, we assessed the expression of cytokines, including IL-2, IFN-gamma, IL-4, and IL-17, in Egr-2-deficient and WT CD4 T cells after TCR ligation. These cytokines are signatures for T cell activation, Th1, Th2, and Th17 differentiation, respectively. CD4+ T cells were isolated from spleens of 3-mo-old mice to avoid complications from the increased percentage of CD44high T cells in older Egr-2 cKO mice. Consistent with the normal primary responses in vitro (Fig. 1 B), IL-2 was up-regulated normally in Egr-2 cKO cells (Fig. 8 A). However, the expression of IFN-gamma, IL-17A, and IL-17F in Egr-2-deficient T cells was much higher than WT (Fig. 8 A). Although IFN-gamma was increased approximately twofold in Egr-2-deficient T cells, the increase in IL-17 was most significant with a four- to fivefold increase compared with WT. Interestingly, IL-4 was reduced in Egr-2-deficient CD4+ T cells (Fig. 8 A). To investigate the relevance of proinflammatory cytokines to the development of autoimmune disease, IFN-gamma- and IL-17-producing T cells, which are the hallmarks of Th1 and Th17, respectively, were analyzed in CD4+ T cells from different ages. In WT mice, the percentage of IFN-gamma-producing cells (approximately1.5-2%) was similar in 3- and 8-mo-old mice, whereas IL-17-producing cells could barely be detected at either age (Fig. 8 B). However, a low level of IL-17-producing cells (approximately1.9%) were detected in WT T cells from mice aged 12 mo, and IFN-gamma-producing cells were also increased to approximately4.5% in these mice (Fig. 8 B). In contrast, a low level of IL-17- (approximately1.5%) and IFN-gamma-producing (approximately5%) T cells could already be detected in T cells from young (3-mo-old) Egr-2 cKO mice, and the percentage of cells producing IL-17 and IFN-gamma progressively increased as the mice aged (IL-17, approximately5% at 8 mo and approximately9% at 12 mo; IFN-gamma, approximately10% at 8 mo and approximately13% at 12 mo; Fig. 8 B).
###end p 37
###begin p 38
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 79 0 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cytokine expression and T cell differentiation of Egr-2&#8211;deficient CD4<sup>+</sup> T cells.</bold>
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 382 383 379 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 543 544 536 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 734 737 723 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 745 749 734 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 927 931 916 920 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 974 975 963 964 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 128 132 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
###xml 781 785 <span type="species:ncbi:10090">mice</span>
Cytokine expression and T cell differentiation of Egr-2-deficient CD4+ T cells. (A) CD4+ T cells from 3-mo-old WT and Egr-2 cKO mice were stimulated without (-) or with anti-CD3 (+) for 6 h and cytokine expression was quantified by real-time RT-PCR. The relative expression of cytokines was normalized to beta-actin mRNA. The results are representative of three experiments. (B) CD4+ T cells from WT and Egr-2 cKO mice of different ages indicated were stimulated for 5 h with PMA and ionomycin before staining with IFN-gamma and IL-17. (C) CD4+ T cells from 8-mo-old mice were stimulated for 5 h with PMA and ionomycin and then stained with CD44, IFN-gamma, and IL-17. The cytokine-positive cells were quantified after gating for CD44low or CD44high. (D) Splenocytes from 8-mo-old mice were stimulated for 5 h with PMA and ionomycin and then stained with CD4, CD44, and the indicated cytokine antibodies. Cytokine-positive CD44high cells were quantified after gating for CD4+ cells.
###end p 38
###begin p 39
###xml 69 73 69 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 121 125 121 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 197 198 197 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 202 206 202 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 378 379 374 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 383 387 379 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 489 490 481 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 494 498 486 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 517 525 509 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 C</xref>
###xml 560 561 552 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 565 568 557 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 651 659 639 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 C</xref>
###xml 750 758 738 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 D</xref>
###xml 794 795 782 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 799 803 787 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 980 988 968 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 D</xref>
###xml 1028 1032 1016 1020 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 511 515 <span type="species:ncbi:10090">mice</span>
###xml 645 649 <span type="species:ncbi:10090">mice</span>
###xml 825 829 <span type="species:ncbi:10090">mice</span>
###xml 974 978 <span type="species:ncbi:10090">mice</span>
###xml 1233 1237 <span type="species:ncbi:10090">mice</span>
We have shown that Egr-2 deficiency leads to the accumulation of CD44high T cells. To determine whether the expanded CD44high T cells in Egr-2 cKO mice are functionally altered, the function of CD4+CD44high T cells in WT and Egr-2-cKO mice at 8 mo of age was assessed by measuring the proportion of IFN-gamma-, IL-2-, IL-4-, and IL-17-producing cells. More than 14 and 7% of CD4+CD44high cells from Egr-2 cKO mice produced IFN-gamma and IL-17, respectively, compared with <4 and <2% of CD4+CD44high cells in WT mice (Fig. 8 C). In contrast, <2 and <0.5% of CD4+CD44low cells produced IFN-gamma and IL-17, respectively, in either Egr-2 cKO or WT mice (Fig. 8 C). However, the percentage of IL-4-producing cells was reduced in Egr-2-deficient T cells (Fig. 8 D). Thus, the large population of CD4+CD44high T cells in Egr-2 cKO mice are predominately Th1 or Th17 type effector T cells. Importantly, the percentage of IL-2-producing T cells was very similar in Egr-2 cKO and WT mice (Fig. 8 D), indicating that the expansion of CD44high T cells in Egr-2 cKO is not caused by enhanced IL-2 expression. These results suggest that hyperproliferation of effector T cells and Th1 and Th17 differentiation are the major disorders in Egr-2 cKO mice.
###end p 39
###begin p 40
###xml 219 220 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
To investigate the mechanisms behind the increased expression of IFN-gamma and IL-17, we examined the expression of T-bet, a Th1 transcription factor, and IL-6, -21, and -23, which can induce Th17 differentiation in CD4+ T cells from aged Egr-2 cKO mice. The expression of these molecules was not altered (unpublished data), suggesting that Egr-2 may be directly involved in regulation of IFN-gamma and IL-17 expression or Th1 and Th17 differentiation.
###end p 40
###begin title 41
DISCUSSION
###end title 41
###begin p 42
###xml 156 160 156 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
In this study, we have discovered that Egr-2 controls the proliferation and tolerance of T cells. Loss of Egr-2 expression leads to the accumulation of CD44high T cells, enhanced expression of proinflammatory cytokines, increased Th1 and Th17 differentiation, and development of a late onset lupuslike autoimmune disease.
###end p 42
###begin p 43
###xml 101 102 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 169 173 169 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 263 267 263 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 324 328 324 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 501 504 501 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 524 528 524 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 650 651 650 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 690 694 690 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 752 755 752 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 812 814 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 848 852 848 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 985 989 985 989 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 1061 1065 <span type="species:ncbi:10090">mice</span>
We and others have previously found that Egr-2 is induced in tolerant T cells after TCR stimulation (7, 8, 9). We have now found that Egr-2 is normally expressed in CD44high T cells, and that Egr-2 deficiency results in a massive accumulation of these cells. CD44high is a marker for effector or memory T cells (2). The CD44high T cells in WT mice raised in a clean environment are presumably generated in response to commensal antigens, gut flora, or self-antigen (2). In contrast to the resting CD44low naive T cells, CD44high cells undergo slow and intermittent proliferation in response to homeostatic stimuli such as self-antigen and cytokines (2), and also it has been found that CD44high memory T cells are intrinsically more sensitive than CD44low naive cells to stimulation through the TCR-CD8 complex (21). The expression of Egr-2 in CD44high cells may be induced from homeostatic responses to serve as a feedback mechanism to control the proliferation and activation of CD44high T cells. The development of systemic autoimmune responses in Egr-2 cKO mice demonstrates the importance of such controls.
###end p 43
###begin p 44
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 732 733 728 729 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 807 808 803 804 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
###xml 755 759 <span type="species:ncbi:10090">mice</span>
###xml 919 923 <span type="species:ncbi:10090">mice</span>
Several findings in predisposed mice appear to support the notion that primary or secondary homeostatic lymphocyte perturbations, such as in MRL/lpr and p21cip1 KO mice of C57BL/6 background, contribute to the pathogenesis of spontaneous lupus (17, 22, 23). These findings suggest that uncontrolled T cell proliferation can lead to T cell expansion and generation of effector cells to self-antigens, resulting in the development of lupuslike systemic autoimmune diseases. Our results indicate that Egr-2 is an intrinsic regulator that controls not only proliferation but also inflammation of effector T cells, and also inhibits the development of lupuslike autoimmune diseases. The accumulation of IFN-gamma- and IL-17-producing CD4+ T cells in Egr-2 cKO mice suggests the possibility that the activated CD4+ T cells are effector inflammatory T cells primed by self-antigen, and that the loss of tolerance in Egr-2 cKO mice leads to the expansion of these cells and autoimmune responses.
###end p 44
###begin p 45
###xml 148 152 148 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 194 197 194 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 885 887 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 1585 1587 1585 1587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 1654 1656 1654 1656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 198 202 <span type="species:ncbi:10090">mice</span>
###xml 345 349 <span type="species:ncbi:10090">mice</span>
###xml 511 515 <span type="species:ncbi:10090">mice</span>
###xml 795 799 <span type="species:ncbi:10090">mice</span>
###xml 941 945 <span type="species:ncbi:10090">mice</span>
###xml 1331 1335 <span type="species:ncbi:10090">mice</span>
###xml 1648 1652 <span type="species:ncbi:10090">mice</span>
We found that the cell cycle inhibitor p21cip1 is a direct target gene of Egr-2. Egr-2 deficiency results in defective expression of p21cip1 in CD44high T cells. Most of the reports from p21cip1-/- mice have shown enhanced T cell activation, proliferation, and autoimmune manifestations (17, 18, 19), which are largely consistent with Egr-2 cKO mice. However, a study in the BXSB atypical lupus model showed that p21cip1 deletion increased apoptosis of activated T cells and decreased disease incidence in male mice suggesting that p21cip1 regulates proliferative responses by blocking apoptosis (24). However, the increased apoptosis in response to TCR stimulation suggests a differential effect of p21cip1 in the activation and proliferative responses of T cells. In a recent study in C57BL/6 mice, p21cip1 deletion only enhanced T cell proliferation at a late stage of stimulation (19), which is consistent with our findings in Egr-2 cKO mice of C57BL/6 background. Collectively, these studies indicate that p21cip1 is involved in the regulation of effector T cell proliferation, but plays only a part of the tolerance program, and its function in lupus development is dependent on the genetic predisposition. Indeed, in addition to the altered expression of p21cip1, enhanced differentiation of Th1 and Th17 cells in Egr-2 cKO mice was found. Although we do not yet know how Egr-2 regulates the expression of proinflammatory cytokines, the accumulation of Th1 and Th17 cells can directly result in infiltration of T cells into multiple organs and inflammatory autoimmune diseases (25). These results have not been reported in p21cip1-deficient mice (17).
###end p 45
###begin p 46
###xml 516 518 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 655 657 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 659 661 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 948 952 <span type="species:ncbi:10090">mice</span>
The increased expression of IFN-gamma and IL-17 in Egr-2-deficient T cells after TCR ligation suggests that Egr-2 may be involved in the control of inflammatory cytokines in effector T cells. Such control may not only be important to prevent inflammatory reactions of autoreactive T cells but also for the reduction of immunopathology during a productive immune response. Although both Th1 and Th17 are observed in most autoimmune models, the mechanisms mediating Th1 and Th17 differentiation in vitro are distinct (25), whereas the in vivo mechanisms are still unknown. NFAT has been found to induce IFN-gamma expression and activate the IL-17 promoter (26, 27). Egr-2 is one of the NFAT target genes in T cells. Therefore, the expression of Egr-2 could act as negative feedback loop to control IFN-gamma and IL-17 expression in response to TCR stimulation. Although we did not find altered activation of NFAT in Egr-2-deficient T cells from aged mice (unpublished data), the possibility that Egr-2 physically interacts with NFAT and inhibits its activity has yet to be analyzed. The reduced production of Th2 cytokines could either result from enhanced Th1 and Th17 differentiation or direct regulation by Egr-2; future investigations will further examine these hypotheses.
###end p 46
###begin p 47
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 600 601 600 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1181 1182 1177 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1244 1245 1240 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 1247 1248 1243 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1284 1285 1280 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1352 1356 1348 1352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 363 367 <span type="species:ncbi:10090">mice</span>
###xml 1378 1382 <span type="species:ncbi:10090">mice</span>
Both Egr-2 and -3 are expressed in double-negative thymocytes, and defective expression of Egr-3 leads to the accumulation of double-negative thymocytes and reduction of DP thymocytes in the thymus (12), indicating that Egr-3 is involved in thymocyte development before thymocyte selection. However, we did not find a similar phenotype in the thymus of Egr-2 cKO mice, suggesting that either Egr-2 function at this stage is redundant or that Cre-mediated deletion was incomplete at this stage. T cell lines overexpressing Egr-2 or -3 show an up-regulation of Cbl-b and reduced production of IL-2 (7, 8). This finding led to the hypothesis that the mechanism for Egr-2 in maintaining T cell tolerance would be down-regulation of TCR signaling. However, we could not detect differences between Egr-2-deficient and WT naive T cells in the major TCR signaling pathways, such as AP1, NF-kappaB, NFAT, and MAP kinase, after TCR stimulation in vitro (Fig. S4 and not depicted). In addition, we did not observe hyperproliferation of naive Egr-2 cKO T cells in response to primary TCR stimulation. This normal response to TCR engagement could be caused by functional compensation by Egr-3 (8). Nevertheless, the continuously proliferating T cell lines (7, 8) and preactivated primary T cells (8) used in these studies share some features of the hyperactive CD44high T cells in Egr-2 cKO mice. Therefore, the negative regulation of T cell activation in these reports is consistent with the hyperproliferation and activation of Egr-2-deficient T cells in vivo.
###end p 47
###begin p 48
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 327 328 327 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 331 332 331 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 335 336 335 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 720 722 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 314 318 <span type="species:ncbi:10090">mice</span>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
Egr-2 has been found to induce FasL expression in T cells (15, 16). Deficiency in Fas expression in MRL/lpr mice results in severe lupuslike disease caused by the resistance of T cells to apoptosis (22, 23). However, Egr-2 deficiency did not alter expression of FasL in T cells or apoptosis in either young or old mice, and CD3+CD4-CD8- T cells were not detected in spleen of old Egr-2 cKO mice (Fig. S5), suggesting distinct mechanisms for lupuslike disease in Egr-2 cKO and MRL/lpr mice. Recently, reduced expression of Egr-2 and -3 has been found in T cells from BALB/c mice after induction of lupuslike disease by an anti-DNA antibody, and the decreased expression was associated with increased IFN-gamma secretion (28), suggesting that Egr molecules are involved in the maintenance of self-tolerance.
###end p 48
###begin p 49
###xml 326 328 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 604 606 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
###xml 514 518 <span type="species:ncbi:10090">mice</span>
Although antinuclear antibodies are hallmarks of systemic lupus, the mechanisms responsible for the breakdown of self-tolerance are still unknown. One of the characteristics of the autoimmune disorder in lupus patients is Th1-mediated inflammation with a high level of IFN-gamma production and increased serum IgG2a antibody (22), both of which we have observed in aged Egr-2 cKO mice. In addition, a massive increase in IL-17 production in activated T cells and an increased percentage of Th17 cells in Egr-2 cKO mice were observed. Th17 plays an important role in the development of lupuslike disease (29). These results suggest that autoimmune disorders can result from a loss of control of effector T cell expansion and inflammatory activation, and that this control is mediated by genes regulated by Egr-2.
###end p 49
###begin p 50
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 569 570 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 634 635 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 710 714 710 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 1502 1506 <span type="species:ncbi:10090">mice</span>
###xml 1531 1536 <span type="species:ncbi:9606">human</span>
Peripheral T cells are tolerant to self-antigens, which is achieved by limiting the expansion and activation of self-reactive T cells (1). In addition to the function of regulatory T cells (5), several intrinsic mechanisms have been discovered that either induce T cell anergy or limit T cell expansion (4), such as the GRAIL E3 ligase, which is induced in anergic T cells and inhibits IL-2 expression by targeting TCR signaling molecules (30). In addition, control of T cell growth and regulation of apoptosis are also important mechanisms to maintain self-tolerance (1). Egr-2 has been found to regulate expression of an E3 ligase (8), and now we show that Egr-2 directly activates p21cip1 expression in CD44high T cells and is involved in the control of Th1 and Th17 differentiation. Our data demonstrate that Egr-2 is an intrinsic regulator of effector T cells and is essential for the control of their proliferation and inflammatory activation in the absence of overt antigen stimulation. The fact that Egr-2 is expressed in effector, but not in naive T cells, and controls their proliferation in vivo without interfering with their responses to optimal TCR stimulation provides insight into how the threshold for T cell activation is regulated, thus enabling the activation and expansion of effector T cells only in response to optimal antigen stimulation and limiting the expansion of hypersensitive or potentially autoreactive cells. The development of systemic autoimmune disease in Egr-2 cKO mice with characteristics of human lupus makes this a good model for further studies into the mechanisms of lupus development and could potentially yield novel therapeutic strategies.
###end p 50
###begin title 51
MATERIALS AND METHODS
###end title 51
###begin title 52
###xml 42 46 <span type="species:ncbi:10090">mice</span>
Generation of conditional Egr-2 knock-out mice.
###end title 52
###begin p 53
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 555 558 555 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 180 195 <span type="species:ncbi:10090">transgenic mice</span>
###xml 523 527 <span type="species:ncbi:10090">mice</span>
###xml 559 563 <span type="species:ncbi:10090">mice</span>
###xml 601 605 <span type="species:ncbi:10090">mice</span>
###xml 717 721 <span type="species:ncbi:10090">mice</span>
Egr-2 cKO mice were generated by crossing floxed Egr-2 mice (obtained from P. Charnay, Institut National de la Sante et de la Recherche Medicale, Paris, France) (14) with hCD2-Cre transgenic mice in which Cre-induced recombination is detected only in T and B cells (13). The primer pairs (p1, 5'-agttgacagcccgagtccagtgg-3'; p2, 5'-gggagcgaagctactcggatacgg-3'; sense 5'-CCAACAACTACCTGTTCTGCCG-3'; antisense 5'-TCATCCTTGGCACCATAGATCAGG-3') were used for genotyping of Egr-2-Loxp and iCre loci, respectively. The Egr-2 floxed mice are used as a control. Rag2-/- mice have been described before (13). All mice used in this study are on the C57BL/6 background or have been backcrossed at least three times to C57BL/6. All mice were maintained in the Biological Services Unit, Barts and The London School of Medicine, and used according to established institutional guidelines under the authority of a UK Home Office project license (Guidance on the Operation of Animals, Scientific Procedures Act 1986). UK home office approved our animal project license for this experiment.
###end p 53
###begin title 54
Antibodies.
###end title 54
###begin p 55
###xml 271 274 <span type="species:ncbi:10116">rat</span>
###xml 280 285 <span type="species:ncbi:10090">mouse</span>
###xml 556 562 <span type="species:ncbi:9986">Rabbit</span>
###xml 568 573 <span type="species:ncbi:9606">human</span>
###xml 653 659 <span type="species:ncbi:9793">donkey</span>
###xml 665 668 <span type="species:ncbi:10116">rat</span>
###xml 704 710 <span type="species:ncbi:9793">donkey</span>
###xml 716 722 <span type="species:ncbi:9986">rabbit</span>
FITC-conjugated antibodies to CD4 and CD62L; PE-conjugated antibodies to CD4, CD8, NK1.1, F4/80, CD25, and CD69; allophycocyanin (APC)-conjugated antibodies to CD44 and Annexin V; peridinin chlorophyll protein (PerCP)-conjugated antibody to CD3, PE-labeled anti-p-stat5, rat anti-mouse B220 antibody for immunohistochemistry, and antibody to CD3 (clone 145-2C11) and CD28 (clone 37.51) for stimulation were obtained from BD Biosciences. FITC-conjugated antibody to IFN-gamma, PE-conjugated antibodies to IL-4, IL-2, and Foxp3 were bought from eBioscience. Rabbit anti-human CD3 antibody for immunohistochemistry was purchased from DAKO. FITC-conjugated donkey anti-rat IgG and Alexa Fluor 594-conjugated donkey anti-rabbit IgG second antibodies were obtained from Jackson Immunoresearch Laboratories. Egr-2 antibody was purchased from Covance.
###end p 55
###begin title 56
Cell isolation and stimulation.
###end title 56
###begin p 57
###xml 11 12 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 134 135 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 139 143 139 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 151 152 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 156 159 156 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 529 530 527 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Primary CD4+ T cells were purified by positive selection using a MACS system (Miltenyi Biotec), with purity consistently >90%. The CD4+CD44high and CD4+CD44low T cells were sorted by FACS after staining with FITC-conjugated CD4, PE-conjugated CD44, and APC-conjugated CD25 antibodies (eBioscience). Cells were gated on CD25- cells to exclude activated cells and regulatory T cells. T cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 50 muM 2-ME, and 100 U/ml penicillin and 100 mug/ml streptomycin. Purified CD4+ T cells were stimulated with 1 mug/ml CD3 and 1 mug/ml CD28 antibody-coated beads, uncoated beads, or IL-2 as indicated.
###end p 57
###begin title 58
Proliferation.
###end title 58
###begin p 59
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 143 144 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 266 267 264 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 729 730 727 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 737 738 735 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 809 810 807 808 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 817 818 815 816 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 948 949 946 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 956 957 954 955 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 336 340 <span type="species:ncbi:10090">mice</span>
###xml 761 765 <span type="species:ncbi:10090">mice</span>
###xml 848 852 <span type="species:ncbi:10090">mice</span>
###xml 925 929 <span type="species:ncbi:10090">mice</span>
To measure proliferation, purified CD4+ T cells (5 x 104 cells/200 mul) in 96-well plates were stimulated in triplicate. A total of 1 muCi of [3H]TdR was added for the last 8 h of culture, and cells were harvested and subjected to scintillation counting to measure [3H]TdR incorporation. To analyze the in vivo proliferation of T cells mice were fed with 0.8 mg/ml BrdU in drinking water for 9 d. The splenocytes were stained with PE-conjugated anti-CD4 or -CD8 antibody and APC-conjugated CD44 antibody, followed by staining with FITC-conjugated anti-BrdU antibody with the BrdU flow kit (BD Biosciences). The percentage of T cells that had incorporated BrdU was analyzed by FACS. The proliferation of adoptively transferred CD4+ or CD8+ T cells in WT C57BL/6 mice was analyzed by CFSE labeling. Purified CD4+ or CD8+ T cells from Egr-2 cKO or WT mice were labeled with CFSE and transferred into syngeneic 12-wk-old C57BL/6 mice. 3-4 wk later, CD4+ or CD8+ T cells were purified from the spleens of recipients and stained with PE-anti-CD44 antibody before analysis of CFSE staining.
###end p 59
###begin title 60
Intracellular cytokine analysis.
###end title 60
###begin p 61
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
Splenocytes or CD4+ T cells harvested from mice of different ages were stimulated with 20 ng/ml PMA plus 0.5 mug/ml ionomycin in the presence of Brefeldin A for 5 h. Cells were then stained for cell surface markers (CD4 and CD44), and intracellular cytokine staining was performed with the Fixation and Permeabilization kit and IFN-gamma, IL-2, IL-4, and IL-17 antibodies in accordance with the manufacturer's instructions (eBioscience).
###end p 61
###begin title 62
Quantitative real-time PCR.
###end title 62
###begin p 63
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 100 101 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 151 152 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 156 159 156 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 167 168 167 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 172 176 172 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
Real-time PCR was performed as previously described (31). In brief, total RNA was extracted from CD4+ T cells before and after stimulation, or from CD4+CD44low and CD4+CD44high cells, using TRIzol (Invitrogen), and was reverse transcribed using oligo(dT) primers (GE Healthcare). Quantitative real-time PCR was performed on a Rotor-Gene system (Corbett Robotics) using SYBR green PCR master mix (QIAGEN). The primers used were as follows: Egr-2 sense 5'-CTTCAGCCGAAGTGACCACC-3' and antisense 5'-GCTCTTCCGTTCCTTCTGCC-3'; p21 sense 5'-TTGCACTCTGGTGTCTGAGC-3' and antisense 5'-GAGGACCAATCTGGGCTTGG-3'; beta-actin sense 5'-AATCGTGCGTGACATCAAAG-3' and antisense 5'-ATGCCACAGGATTCCATACC-3'; IL-2 sense 5'-GCATGTTCTGGATTTGACTC-3' and antisense 5'-CAGTTGCTGACTCATCATCG-3'; IL-4 sense 5'-CAAACGTCCTCACAGCAACG-3' and antisense 5'-CTTGGACTCATTCATGGTGC-3'; IL-17A sense 5'-AGCGTGTCCAAACACTGAGG-3' and antisense 5'-CTATCAGGGTCTTCATTGCG-3'; IL-17F sense 5'-AACCAGGGCATTTCTGTCCC-3' and antisense 5'-TTTCTTGCTGAATGGCGACG-3'; and IFN-g sense 5'-CCATCAGCAACAACATAAGC-3' and antisense 5'-AGCTCATTGAATGCTTGGCG-3'.
###end p 63
###begin p 64
###xml 283 315 280 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">(CT&#946;-actin-CTtarget) &#215; 10,000</sup>
The data were analyzed using the Rotor-Gene software. All samples were run in duplicate, and relative mRNA expression levels were obtained by normalizing against the level of beta-actin from the same sample under the same program using the following equation: relative expression = 2(CTbeta-actin-CTtarget) x 10,000.
###end p 64
###begin title 65
Immunoblotting.
###end title 65
###begin p 66
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 536 537 530 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
Total cellular protein or cytosolic and nuclear extracts were prepared from CD4+ T cells before and after stimulation, as previously described (9). Nuclear proteins were finally dissolved in 20 mM Hepes, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, and protease and phosphatase inhibitors (Roche), and the aliquots were frozen at -80degreesC. Protein concentration was determined using the BCA method (Sigma-Aldrich) according to the manufacturer's instructions. Immunoblotting was performed as in our previous study (9).
###end p 66
###begin title 67
EMSA.
###end title 67
###begin p 68
###xml 44 46 44 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 130 132 126 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 628 630 623 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
EMSA was performed as previously described (31). In brief, the p21 probe (5'-GGGCTGCCTCTGAGGGGGCGGGGC-3') was labeled with [alpha-32P]dCTP using Ready-to-Go DNA labeling beads (GE Healthcare) according to the manufacturer's instructions. This was then purified using ProbeQuant G-50 microcolumns (GE Healthcare), and binding reactions were performed with nuclear extracts from stimulated and unstimulated MF2.2D9 cells in 10 mM Hepes, pH 7.5, 50 mM KCl, 2.5 mM MgCl2, 10 mM DTT, 1 mug poly(dI-dC), 10% glycerol, 0.5 mM ZnCl2, and 5 mM spermidine. The reactions were incubated at room temperature for 40 min with double-stranded 32P-labeled oligonucleotide. For supershift reactions, anti-Egr-2 and anti-Egr-3 antibody were added after 10 min of incubation. The samples were electrophoresed on 5% polyacrylamide gels in 0.5x TBE. The gels were dried under vacuum and exposed to autoradiographic film at -80degreesC.
###end p 68
###begin title 69
Retroviral transduction.
###end title 69
###begin p 70
###xml 393 399 <span type="species:ncbi:10090">murine</span>
pBabe Egr-2, provided by K. Jessen (University College London, London, England) was transfected into the Phoenix packaging cell line using FuGene according to the manufacturer's instructions. Retrovirus containing supernatant was collected 48 h later. This was added to a RetroNectin (Takara)-coated plate and incubated at 32degreesC for 4 h. The plates were washed with PBS, and then MF2.2D9 murine T hybridoma cells, provided by K.L. Rock (University of Massachusetts Medical School, Worcester, MA) were added. Cells were expanded and GFP-positive cells were isolated by FACS.
###end p 70
###begin title 71
ChIP.
###end title 71
###begin p 72
###xml 78 79 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
ChIP assays were performed according to the protocol supplied by Millipore. 108 Egr-2 and GFP-transduced MF2.2D9 cells were cross-linked with 1% formaldehyde for 10 min at room temperature. After quenching of formaldehyde with 125 mM glycine, chromatin was sheared by sonication. The size of sonicated chromatin was approximately300-1,000 bp as analyzed on agarose gels. Fragmented chromatin (500 mug) was precleared for 1 h with salmon sperm DNA/BSA-blocked protein A beads (GE Healthcare) and subjected to immunoprecipitation with specific anti-Egr-2 Ab (Covance) or control antibody at 4degreesC overnight. Immunocomplexes were recovered by incubation with blocked protein A beads and washed in low salt, and then high salt, and finally LiCl buffer. DNA was purified by phenol chloroform extraction and used as template for PCR with specific oligonucleotides p21 sense (5'-ATCGGTGAAGGAGTGGGTTGGTCC-3'), p21 antisense (5'-ACACCTCTCGGCTGCTGCAGTTGG-3'), SOCS3 sense (5'-TGTGTACTCAAGCTGGTGCAC-3'), and SOCS3 antisense (5'-CATACTGATCCAGGAACTCC-3').
###end p 72
###begin title 73
Histological and serological analysis.
###end title 73
###begin p 74
###xml 709 711 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 363 369 <span type="species:ncbi:9986">rabbit</span>
###xml 375 380 <span type="species:ncbi:9606">human</span>
###xml 389 392 <span type="species:ncbi:10116">rat</span>
###xml 398 403 <span type="species:ncbi:10090">mouse</span>
###xml 487 493 <span type="species:ncbi:9793">donkey</span>
###xml 499 505 <span type="species:ncbi:9986">rabbit</span>
###xml 530 536 <span type="species:ncbi:9793">donkey</span>
###xml 542 545 <span type="species:ncbi:10116">rat</span>
###xml 753 759 <span type="species:ncbi:9793">donkey</span>
###xml 765 770 <span type="species:ncbi:10090">mouse</span>
###xml 863 867 <span type="species:ncbi:9925">goat</span>
###xml 873 878 <span type="species:ncbi:10090">mouse</span>
Tissues were fixed with 10% formalin in PBS and embedded in paraffin. Sections were stained with hematoxylin and eosin by standard methods. Histological examination of kidneys was done in a blind manner. Proteinuria was determined using reagent strips for urinalysis, URS-5K (Access Diagnostics Tests). For immunohistochemistry, kidney sections were stained with rabbit anti-human CD3 and rat anti-mouse B220. After washing, sections were further stained with Alexa Fluor 594-conjugated donkey anti-rabbit IgG and FITC-conjugated donkey anti-rat IgG secondary antibodies, followed by counterstaining with DAPI. For analysis of Ig deposits, 6 mum frozen kidney sections were processed as previously described (32) and stained with a Texas red-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch Laboratory). Total serum IgG and Ig isotypes were captured with goat anti-mouse Ig, and concentrations were determined by ELISA with HRP-conjugated antibodies against IgG, IgG1, IgG2a, IgG2b, and IgM (Sigma-Aldrich). Reactivity of these antibodies was normalized for equivalent OD against total IgG and the corresponding isotype controls (Sigma-Aldrich).
###end p 74
###begin p 75
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 132 136 <span type="species:ncbi:9913">Calf</span>
###xml 598 604 <span type="species:ncbi:9986">rabbit</span>
###xml 610 615 <span type="species:ncbi:10090">mouse</span>
The levels of anti-histone and anti-dsDNA antibodies in serum were measured according to published methods (33). In brief, 5 mug/ml Calf thymus DNA or histones (Sigma-Aldrich) in PBS were coated at 0.2 ml/well in Immulon II microtiter plates (Dynatech Laboratories., Inc.). After overnight incubation at 4degreesC, wells were postcoated with 0.4 ml gelatin (1 mg/ml in PBS) for 2 h at 37degreesC. After washing, 0.2 ml of serum samples diluted 1:1,000-1:4,000 in 0.1% Tween, 1 mg/ml gelatin, and 0.5% BSA in PBS were added and incubated for 1.5 h at room temperature. After washing, HRP-conjugated rabbit anti-mouse Ig (Dako) diluted 1:4,000 in 0.1% Tween in PBS was added. After 1.5 h of incubation at room temperature, the wells were washed and substrate solution was added. The OD was then read with an automated spectrophotometer at 492 nm.
###end p 75
###begin title 76
Adoptive transfer.
###end title 76
###begin p 77
###xml 179 180 179 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 273 274 273 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 278 279 278 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 332 333 332 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 380 381 380 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 385 386 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 430 431 430 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 604 607 603 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
###xml 370 374 <span type="species:ncbi:10090">mice</span>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
###xml 475 479 <span type="species:ncbi:10090">mice</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
T cell-depleted splenocytes were prepared from Egr-2 cKO and WT mice aged 8 mo using a Pan T cell isolation kit (Miltenyi Biotec), according to the manufacturer's protocol and CD4+ T cells were isolated by positive selection with CD4 (L3T4) microbeads (Miltenyi Biotec). 106 CD4+ T cells from Egr-2 cKO mice were mixed with 1.5 x 106 T cell-depleted splenocytes from WT mice or 106 CD4+ T cells from WT mice were added to 1.5 x 106 T cell-depleted splenocytes from Egr-2 cKO mice. These mixtures were suspended in 100 mul of physiological saline and injected i.v. into the dorsal tail vein of female Rag2-/- mice at 12 wk of age. 75 d after transfer, serum antibodies against dsDNA and histones were measured.
###end p 77
###begin title 78
Statistics.
###end title 78
###begin p 79
###xml 17 18 17 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
The Mann-Whitney U test was used. The normality of data distribution and the homogeneity of variances of the data were verified by the K-S Lilliefors and Cochran C tests, respectively.
###end p 79
###begin title 80
Online supplemental material.
###end title 80
###begin p 81
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 477 481 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows the results of genotyping of Egr-2 cKO mice and Egr-2 expression in B and T cells. Fig. S2 shows development of thymocytes in Egr-2 cKO mice comparing to WT mice. Fig. S3 shows the subgroups of lymphocytes in spleens of WT and Egr-2 mice. Fig. S4 shows ERK and STAT5 activation in T cells after TCR ligation. Fig. S5 shows the results of apoptosis analysis of CD4 T cells. Fig. S6 displays percentage of NK, macrophage, and B cells in spleens of WT and Egr-2 cKO mice. The online supplemental material is available at . The online version of this article is available at .
###end p 81
###begin title 82
Supplementary Material
###end title 82
###begin title 83
[Supplemental Material Index]
###end title 83
###begin p 84
###xml 54 58 <span type="species:ncbi:10090">mice</span>
We thank Dr. Patrick Charnay for providing Egr-2-loxp mice and Dr. Kristjan Jessen for pBabe Egr-2. We thank Mr. Steven Pash and Mrs. Christine Newton, Biological Science, Brunel University, UK for technical support. We also thank Dr. Matthias Merkenschlager Imperial College, London for advice on the Chip assay, and Dr. Gary Warnes for assistance with FACS analysis.
###end p 84
###begin p 85
This work was supported by the Biotechnology and Biological Sciences Research Council and the Medical Research Council. D.C. Wraith is supported by Wellcome Trust.
###end p 85
###begin p 86
The authors have no conflicting financial interests.
###end p 86

